LCTX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 16:00):

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally...

Stats
Today's Volume	305 552
Average Volume	955 247
Market Cap	214.93M
EPS	$0 ( 2024-03-07 )
Next earnings date	( $-0.0400 ) 2024-05-09
Last Dividend	$0.0800 ( 2003-12-15 )
Next Dividend	$0 ( N/A )
P/E	-9.50
ATR14	$0.00300 (0.27%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-07	Culley Brian M	Buy	1 900 000	Employee Stock Option (Right to Buy)
2024-03-07	Samuel George A. Iii	Buy	650 000	Employee Stock Option (Right to Buy)
2024-03-07	Howe Jill Ann	Buy	650 000	Employee Stock Option (Right to Buy)
2024-02-11	Samuel George A. Iii	Sell	6 076	Restricted Stock Units
2024-02-11	Samuel George A. Iii	Buy	6 076	Common Shares, no par value

INSIDER POWER
98.13
Last 93 transactions
Buy: 20 710 358 \| Sell: 1 476 683

Volume Correlation

Long: 0.21 (neutral)

Short: -0.13 (neutral)

Signal:(58.928) Neutral

Lineage Cell Therapeutics Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Lineage Cell Therapeutics Correlation - Currency/Commodity

-0.41
( neutral )

-0.42
( neutral )

0.00
( neutral )

0.66
( moderate )

Lineage Cell Therapeutics Financials

Annual	2023
Revenue:	$8.95M
Gross Profit:	$7.58M (84.76 %)
EPS:	$-0.120

FY	2023
Revenue:	$8.95M
Gross Profit:	$7.58M (84.76 %)
EPS:	$-0.120

FY	2022
Revenue:	$14.70M
Gross Profit:	$13.98M (95.05 %)
EPS:	$-0.160

FY	2021
Revenue:	$3.90M
Gross Profit:	$2.47M (63.40 %)
EPS:	$-0.260

Financial Reports:

No articles found.

Lineage Cell Therapeutics Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Lineage Cell Therapeutics Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	$0.0800	2003-12-15
Last Dividend	$0.0800	2003-12-15
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	$0.0800	--
Avg. Dividend % Per Year	0.00%	--
Score	0.01	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-04-27)

$0 Estimate 0.00 %

Dividend Stability

0.00 Very Bad

Dividend Score

0.01

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for AMEX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
NRO	Ex Dividend Knight	2023-09-14	Monthly	0.00%
COHN	Ex Dividend Junior	2023-08-17	Semi-Annually	0.00%
GLU	Ex Dividend Knight	2023-10-16	Monthly	0.00%
NBW	Ex Dividend Knight	2023-09-28	Monthly	0.00%
VFL	Ex Dividend Knight	2023-09-21	Monthly	0.00%
CDX	Ex Dividend Knight	2023-07-26	Monthly	0.00%
FEN	Ex Dividend Knight	2023-07-21	Quarterly	0.00%
SIFI	Ex Dividend Junior	2023-09-01	Bi-Monthly	0.00%
BHB	Ex Dividend Knight	2023-08-15	Quarterly	0.00%
ERH	Ex Dividend Knight	2023-09-11	Monthly	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-2.41	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.213	1.200	-7.10	-8.52	[0 - 0.3]
returnOnEquityTTM	-0.313	1.500	-4.59	-6.89	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	2.14	0.800	4.30	3.44	[1 - 3]
quickRatioTTM	2.02	0.800	2.84	2.27	[0.8 - 2.5]
cashRatioTTM	1.973	1.500	0.148	0.222	[0.2 - 2]
debtRatioTTM	0.0292	-1.500	9.51	-10.00	[0 - 0.6]
interestCoverageTTM	56.86	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	-0.165	2.00	-0.0551	-0.110	[0 - 30]
freeCashFlowPerShareTTM	-0.169	2.00	-0.0847	-0.169	[0 - 20]
debtEquityRatioTTM	0.0465	-1.500	9.81	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.905	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	-2.77	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-9.68	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0.0885	0.800	-2.74	-2.19	[0.5 - 2]
Total Score				-0.295

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-9.15	1.000	-1.025	0	[1 - 100]
returnOnEquityTTM	-0.313	2.50	-2.95	-6.89	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.169	2.00	-0.0564	-0.169	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.165	2.00	-0.0551	-0.110	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.0593	1.500	-2.94	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-3.19	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-2.30

Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.